FDA Grants Breakthrough Therapy Designation to Incyte's First-in-Class mutCALR-Targeted Antibody for Essential Thrombocythemia
核心洞察
The FDA has granted Breakthrough Therapy designation to INCA033989, Incyte's first-in-class mutant calreticulin (搜索)-targeted monoclonal antibody for treating essential thrombocythemia (搜索) patients with Type 1 CALR (搜索) mutations.
INCA033989 demonstrated rapid and durable normalization of platelet counts in Phase 1 trials, with greater responses observed at higher doses across both mutation types.
Incyte plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (搜索) patients with all types of CALR (搜索) mutations in mid-2026.
The U.S. Food and Drug Administration has granted Breakthrough Therapy designation to INCA033989, Incyte's first-in-class mutant calreticulin (搜索) (mutCALR)-targeted monoclonal antibody, for treating patients with essential thrombocythemia (搜索) (ET) harboring a Type 1 CALR (搜索) mutation who are resistant or intolerant to at least one cytoreductive therapy.
The designation was supported by early Phase 1 data demonstrating the antibody's potential to transform treatment for ET patients, who currently face limited therapeutic options. INCA033989 represents a novel approach targeting only malignant cells while sparing normal cells in patients with myeloproliferative neoplasms.
Clinical Significance and Unmet Medical Need
Essential thrombocythemia (搜索) is a chronic myeloproliferative neoplasm (搜索) characterized by persistently elevated platelet counts due to abnormal blood cell production in the bone marrow. Patients with ET face increased risks for blood clots and bleeding, with some progressing over time to myelofibrosis (搜索) or acute leukemia (搜索).
CALR (搜索) mutations represent the second most common oncogenic driver mutation in ET, occurring in approximately 25% of patients. Among these, the 52-bp deletion known as Type 1 mutation occurs in 55% of patients with CALR mutations and is associated with the highest risk of transformation to myelofibrosis (搜索) among all ET patients.
Promising Phase 1 Results
Preliminary Phase 1 data presented at the 2025 European Hematology Association Congress showed that INCA033989 was well-tolerated and demonstrated rapid and durable normalization of platelet counts across evaluated doses. The study revealed greater responses at higher doses across both mutation types, supporting the drug's therapeutic potential.
"Incyte has long been committed to improving outcomes for patients with MPNs, and this Breakthrough Therapy designation underscores the potential of INCA033989 to be a novel therapy that could significantly transform the treatment of ET patients, who today have limited treatment options," said Pablo J. Cagnoni, M.D., President and Head of Research and Development at Incyte.
Development Timeline and Regulatory Strategy
The Breakthrough Therapy designation allows Incyte to expedite the development pathway for INCA033989 in patients with Type 1 mutations. The company plans to initiate a Phase 3 program evaluating INCA033989 in ET patients with all types of CALR (搜索) mutations in mid-2026, following alignment with regulators in the first half of next year.
Following discussions with regulatory agencies, Incyte plans to initiate a registrational program evaluating patients with ET with Type 1 or non-Type 1 CALR (搜索) mutations who are resistant or intolerant to at least one cytoreductive therapy in the first half of next year.
Upcoming Data Presentations
Updated results from the Phase 1 dose escalation and expansion trial are planned for presentation at the 2025 ASH Annual Meeting in Orlando. The presentation will include updated safety and efficacy data for INCA033989 in ET, along with new data in myelofibrosis (搜索), scheduled for Session 634, Publication #1024, on December 8 from 4:30-6:00 p.m. ET.
Targeting mutCALR: A Novel Therapeutic Approach
Calreticulin (搜索) is a protein involved in regulating cellular calcium levels and normal protein folding. Somatic DNA mutations in the CALR (搜索) gene can result in abnormal protein function, leading to the development of myeloproliferative neoplasms. In essential thrombocythemia (搜索) and myelofibrosis (搜索), CALR mutations occur in approximately 25-35% of patients.
INCA033989 represents Incyte's commitment to developing novel therapies that target only malignant cells while sparing normal cells, offering a potentially transformative treatment approach for patients with mutCALR-driven myeloproliferative neoplasms.